The Liver Humanized CYP3A4 Mouse was developed by Alfred Schinkel at the Netherlands Cancer Institute. The model was generated by targeting of the Cyp3a13 gene in 129P2/OlaHsd-derived E14 ES cells to replace the putative promoter region and exons 1 and 2 with a Pgk-hygromycin cassette. Targeted ES cells were injected into blastocysts. Resultant chimeras were backcrossed to FVB/N for at least seven generations. To generate the cluster deletion, the intronic sequence between exon 2 and 3 of Cyp3a57 was replaced with a neo cassette containing a loxP site, and a hygromycin cassette with a loxP site was inserted downstream of the Cyp3a59 gene in 129P2/OlaHsd-derived E14 ES cells through gene targeting. Transfection of the ES cells with cre recombinase resulted in the deletion of Cyp3a57, Cyp3a16, Cyp3a41, Cyp3a44, Cyp3a11, Cyp3a25 and Cyp3a59. The targeted ES cells were injected into blastocysts. Resultant chimeras were backcrossed two generations to FVB/N. Mice with the cluster deletion were then backcrossed to the Cyp3a13 targeted mutation line for at least four generations to generate a model with disruption or deletion of all eight full-length mouse Cyp3a genes. The Tg(APOE-CYP3A4)A1Ahs transgene was generated by microinjection into FVB/N zygotes. The Cyp3a knockout line was backcrossed to the Tg(APOE-CYP3A4)A1Ahs line for at least three generations. Taconic received stock in 2008, and the line was embryo transfer derived by mating male and female mice homozygous for both targeted regions and homozygous for the transgene. The line was maintained by mating male and females homozygous for the Cyp3a13 disruption, the cluster deletion and the transgene.